Dayab Asad
Research Subjects
Dayab Asad has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Fakhar Latif
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Moeez Akram
Department of Medicine
1 shared publication - Mohammad Saiem Shahzad
Department of Medicine
1 shared publication - Muhammad Adil Obaid
Jinnah Sindh Med Univ, Dept Med, Karachi, Pakistan
1 shared publication - Muhammad Hamza Khan
Karachi Medical and Dental College Karachi Pakistan
1 shared publication - Muhammad Ishtiaq Obaid
Department of Medicine
1 shared publication
Latest Publications
- Open Access
- 30 September 2024
- Published by Taylor & Francis in Future Science OA
- Vol. 10 (1) , 2400797
Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
Aim: The study aimed to explore the incidence of cancer as an adverse event to SGLT2 inhibitors (SGLT2i) use in Type 2 diabetes.Materials & methods: The study followed PRISMA guidelines to pool RCTs conforming the inclusion criteria. Random effects model was used to pool risk ratios.Results & conclusion: After reviewing 19 studies, the analysis suggested a possible increased risk of reproductive, breast, thyroid, hematologic/lymphatic, urinary, skin and skeletal cancers with SGLT2i use. Conversely, lower incidences of respiratory and cardiovascular cancers were noted. However, these associations lacked statistical significance. Caution is advised in using SGLT2i due to potential cancer risks, especially in diabetic patients prone to cancer. More RCTs are essential due to limited research in this area.
- 30 September 2024
- Published by Taylor & Francis in Future Science OA
- Vol. 10 (1) , 2400797
Open AccessRelationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
Aim: The study aimed to explore the incidence of cancer as an adverse event to SGLT2 inhibitors (SGLT2i) use in Type 2 diabetes.Materials & methods: The study followed PRISMA guidelines to pool RCTs conforming the inclusion criteria. Random effects model was used to pool risk ratios.Results & conclusion: After reviewing 19 studies, the analysis suggested a possible increased risk of reproductive, breast, thyroid, hematologic/lymphatic, urinary, skin and skeletal cancers with SGLT2i use. Conversely, lower incidences of respiratory and cardiovascular cancers were noted. However, these associations lacked statistical significance. Caution is advised in using SGLT2i due to potential cancer risks, especially in diabetic patients prone to cancer. More RCTs are essential due to limited research in this area.